Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...

By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...

The natural GLP-1 hormone survives in the body for only a few minutes before it is broken down. Drug developers overcome this ...

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.

Obesity has become a growing concern worldwide, and GLP-1 drugs have brought relief to millions struggling with weight ...

With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising ...

Pfizer announced Friday that it is discontinuing development of its twice-daily weight loss pill danuglipron after a clinical trial showed "high rates" of adverse side effects among users. The ...

Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost significant weight but had trouble tolerating the ...

The enormous popularity of new weight-loss drugs often eclipses the downsides: the burden of weekly injections, rough ...